Home › Amyloidosis › NCT07218705

A Study Of MCG In Cardiac Amyloidosis

A Prospective Study of Magnetocardiography for Disease Detection and Monitoring Treatment Outcomes in Amyloidosis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria

1. Age ≥ 18 years on the date of consent
2. Ability for participant to comply with study requirements
3. Written informed consent

Exclusion Criteria

1. Pregnant or breastfeeding
2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG
3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).
4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
5. Inability to lie down in a supine/inclined position and stay still on the examination bed
6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

About the study

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

What is being tested

• SandboxAQ CardiAQ Magnetocardiography (device)

Sponsor: Mayo Clinic · Participants: 500 · Started: Dec 3, 2025

Contact the study team

• Andy Dang · Phone: 507-255-7752

Official record on ClinicalTrials.gov — NCT07218705

Locations in the U.S.

Conditions

• Amyloidosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.